3/19
08:09 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
3/19
05:49 am
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
2/29
10:49 am
mrsn
Rating for MRSN
Medium
Report
Rating for MRSN
2/29
10:49 am
mrsn
Rating for MRSN
Medium
Report
Rating for MRSN
2/29
08:09 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
2/29
07:16 am
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
2/29
07:16 am
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
2/29
05:55 am
mrsn
Rating for MRSN
Medium
Report
Rating for MRSN
2/29
05:55 am
mrsn
Rating for MRSN
Medium
Report
Rating for MRSN